Back

Addex raises $2.8 million as first-half net loss reaches CHF 3.456 million

Verifying
  • Addex Therapeutics raised USD 2.8 million through an At the Market offering.
  • Cash totaled CHF 0.8 million on June 30, 2026, versus CHF 2.3 million.
  • Neurosterix continued Phase 1 development of its NTX-253 M4 candidate.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.